Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...

Eli Lilly has launched Mounjaro in India, a new once-weekly injectable drug for type 2 diabetes and weight management.

Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...

Another popular diabetes and weight-loss drug, Ozempic (semaglutide), manufactured by Novo Nordisk, has already established a ...

Obesity affects approximately 100 million Indian adults and is linked to over 200 health complications, including heart ...

Eli Lilly launched its weight loss drug Mounjaro in India. According to the company, the injection is supposed to be taken ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

The popular anti-obesity drug Mounjaro has finally been launched in India. The development comes after Eli Lilly received ...